 Theravance Biopharma Inc NASDAQ: TBPH has voluntarily discontinued its Phase 2 study of izencitinib gut-selective oral pan-JAK inhibitor in Crohns disease Study 0173. The decision follows the planned review of trial data by the independent data monitoring committee, which determined concerns about the ongoing benefit-risk of continuing the trial. 